Cambridge, Massachusetts-based Acceleron Pharma, Inc., is now recruiting adults with FSH muscular dystrophy for a Phase 2 clinical trial of ACE-083. The initial trial site is located in St. Louis,… Read More »
Acceleron’s ACE-083 clinical trial is now open
Help us advance FSHD research by taking our survey
Take the survey now! Click here. The FSH Society is participating in an international workshop on FSHD patient registries later this week. We would like to share the patient and family perspective on… Read More »
What Would You Like to #AskTheResearcher?
For the past 25 years, countless researchers have dedicated their time and energy striving to find a cure for FSHD. Thanks to the work of researchers like Dr. Jeffrey Statland,… Read More »
aTyr Pharma Receives FDA Fast Track Designation for Resolaris™
— First Reported Fast Track Designation for a FSHD Treatment — SAN DIEGO, Oct. 24, 2016 /PRNewswire/ — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and… Read More »
Acceleron to host webcast on FSHD clinical trial
(Via BusinessWire.) Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that it… Read More »